QUOTE AND NEWS
TheStreet.com  Feb 27  Comment 
NEW YORK (The Deal) -- United Therapeutics is a rare example of a biotech startup that managed to thread the needle. The company was founded in 1996 by CEO Martine Rothblatt, who was already a wildly successful entrepreneur, co-founding Sirius...
Market Intelligence Center  Feb 25  Comment 
United Therapeutics (UTHR) was selected by MarketIntelligenceCenter.com’s trade-picking algorithms today after trading between $148.04 and $157.37 on Tuesday before closing at $155.16. A diagonal spread using a long position in the Jan. '16...
Market Intelligence Center  Feb 24  Comment 
United Therapeutics (UTHR) presents a trading opportunity that offers a 6.42% return in just 80 days. A covered call on United Therapeutics at the $150.00 level expiring on May. '15 offers an assigned return rate of 6.42% or 29.29% annualized....
Market Intelligence Center  Feb 12  Comment 
A covered call identified by MarketIntelligececenter.com's patented algorithms on United Therapeutics (UTHR) could yield about 7.79% (30.91% annualized, for comparison purposes only) in 92 days. Pair a long position in the stock with the May. '15...
FierceBiotech  Feb 11  Comment 
SteadyMed Therapeutics is heading to Nasdaq in search of $55 million (€49 million) to finance its assault on United Therapeutics' slice of the pulmonary arterial hypertension (PAH) market. The goal is to win market share by offering patients a...
Market Intelligence Center  Feb 6  Comment 
United Therapeutics (UTHR) is a good candidate for a covered call at the $140.00 level. The May. '15 call at that price should fetch a credit of about $12.60, which means the entire position has a net debit of about $129.32. This trade has 4.70%...
Market Intelligence Center  Jan 16  Comment 
For a hedged play on United Therapeutics (UTHR) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a May. '15 $135.00 covered call for a net debit in the $124.94 area. That is also the break-even stock price for the...
Benzinga  Jan 6  Comment 
BTIG initiated coverage on United Therapeutics Corporation (NASDAQ: UTHR) Monday with a Neutral rating. Analyst Hartaj Singh believed a “late-2017 patent cliff for 3 out of 4 of its top products that could reduce 2018 adjusted EPS to 2013...
Benzinga  Dec 11  Comment 
Analysts at Credit Suisse downgraded United Therapeutics (NASDAQ: UTHR) from Neutral to Underperform. The price target for United Therapeutics has been raised from $100 to $120. United Therapeutics shares have surged 44.98% over the past 52...
Benzinga  Dec 11  Comment 





You may also be interested in articles related to United Therapeutics (UTHR):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki